InNexus Announces Achieving Business Milestone in Development of Intracellular SuperAntibody(TM) Therapeutics TSX.V: IXS OTC BB: IXSBF VANCOUVER, March 14 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., an innovative antibody-driven drug development company, announces the achievement of a business milestone in the development of intracellular SuperAntibody(TM) therapeutics. With the receipt of the first of three high affinity anti-apoptosis monoclonal antibodies from its co-development partner, Epitomics, Inc., InNexus has established an important foundation on which to advance SuperAntibody(TM) platform based drugs from early-stage testing to eventual commercialization. Commenting on the announcement, Dr. A. Charles Morgan, President of InNexus, said: "The antibody transfer marks an early and critical milestone in the development of intracellular SuperAntibody(TM) therapeutics. Utilizing our TransMAb(TM) technology platform, the newly enhanced TransMab antibodies will be able to enter inside cells to either turn on or turn off the apoptotic process, leading to the creation of new, useful and never before seen medications in areas as stroke and cancer." Garth Likes, Vice President of Business Development added: "Using our TransMAb(TM) technology platform, we are able to regulate cellular functions and believe it represents a new paradigm in the use of antibodies and SuperAntibodies(TM) for the development of novel therapeutics and diagnostics." Apoptosis is the normal biochemical process in cells which triggers the eventual death of a cell, a process required for the body to grow and become fully formed. Defective apoptotic processes have been implicated in a wide variety of diseases, sometimes causing premature cell-loss disorders, such as in the case of stroke and heart attack. Additionally, it is thought some forms of cancer may result when apoptosis is somehow interrupted, allowing cells to grow unchecked, resulting in a cancerous tumour. Under the terms of the co-development agreement, Epitomics will supply humanized antibodies for defined intracellular targets with InNexus enhancing these antibodies with its TransMAb(TM) technology platform, enabling intracellular delivery. The companies are jointly developing therapeutic, diagnostic and life science products. About Epitomics Epitomics, Inc. is a privately held biotechnology company that develops and commercializes its proprietary rabbit monoclonal antibody technology for use in the research community, diagnostic and therapeutic markets through licensing, service and product sales. Epitomics also has a novel humanization technology. Epitomics has headquarters in Burlingame, California, and a wholly owned subsidiary in Hangzhou, China and has worked with Sugen, Genentech, Upstate USA, Exelixix and Ventanna to name a few. For more information, please visit http://www.epitomics.com/ About InNexus InNexus is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody(TM) and TransMAbs(TM), which improve the potency of existing antibody products while opening new markets and disease applications. Both platforms utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia, Canada and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus please visit http://www.innexusbiotech.com/ This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities. On behalf of the Board of Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A. Charles Morgan President Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788 The TSX Venture Exchange has neither approved nor disapproved of the information contained herein. DATASOURCE: InNexus Biotechnology, Inc. CONTACT: Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788,

Copyright